PitchBook clients can access the full report via the Research Center on the PitchBook Platform.
Pharma biotools VC rebounds as AI-driven platforms lead 2025 funding
The pharma biotools sector regained momentum in 2025 as venture funding rebounded following three years of contraction, driven by investor appetite for asset-light business models and AI-enabled technologies that support drug discovery and development. Deal value rose modestly for the year and remained stable in Q4, signaling a normalization of activity rather than renewed decline. Investment concentrated heavily in generative AI, quantum computing, microfluidics, and synthetic biology, as companies delivering high-fidelity data generation, automation, and software-like services attracted outsized interest. Major Q4 financings for AI-driven protein design platforms and automation-focused tools underscored how investors are backing the emerging “scientific stack” that connects computational discovery with physical experimentation.
Pharma biotools VC deal activity rebounded in 2025, with deal value reaching $5.7 billion and deal count surging to a record 537—signaling renewed investor confidence after three years of contraction.
M&A activity remained subdued, although Halozyme Therapeutics’ acquisition of Elektrofi for up to $900 million marked the sector’s largest exit since 2021 and highlighted continued demand for technologies embedded in biologics delivery and manufacturing workflows. China also emerged as a key growth market, with deal count rising more than 80% YoY and investment concentrated in AI-driven platforms and enabling infrastructure for next-generation therapeutics. Overall, pharma biotools VC activity is stabilizing as investors prioritize platforms capable of generating high-quality datasets, enabling automation, and accelerating commercialization across the broader biopharma ecosystem.